Part I: How to Define the Value of Prescription Drugs to Ensure Patient Access

May 23, 2019 4:00 PM - 6:00 PM

MassBio, 300 Technology Square 8th Fl, Cambridge MA, 02139

Registration Closed

For a growing number of therapies, especially specialty drugs, manufacturers can no longer assume payer coverage and patient access based on regulatory approval alone. Increasingly, manufacturers are being asked to first demonstrate the “value” of the drug – to patients and to the health care system – and thus, justify its price, before being added to a formulary. The challenge? There is no objective or shared measure of value or method for measuring it.

This event, Part I in a three part series that will explore the value of health, will focus on the changing pricing, access and reimbursement landscape early to mid-stage biopharma companies are facing, and give recommendations about what actions they should take to ensure patient access when their drug comes to market, including:

Assessing how different healthcare stakeholders think about value
Understanding how the industry and manufacturers can best make the case for value
Examining the growing use of health technology assessments in determining value
Understanding the implementation of innovative payment methods such as value-based arrangements
Learning about the importance of real-world evidence in determining value over time and for future therapies

We believe this issue is especially timely. We’re at an inflection point, with science that’s been tested for decades finally becoming a reality for patients and a payer system that has not caught up with this level of innovation. Myriad factors are combining to alter the status quo – with policymakers demanding action, and healthcare stakeholders agreeing that we must come up with real solutions. If we don’t come together and address the value equation as an industry and ensure patient access to all new therapies, government or other stakeholders will – and they will likely get it wrong.

Drinks and appetizers will be provided. If you're not a MassBio member but are interested in attending, please email communications@massbio.org.

Stacy Coen
Vice President Of Business Development at Editas Medicine
Stacy joined Editas Medicine as Vice President of Business Development in 2017. She has more than 20 years of experience in Corporate and Business Development in the life sciences industry. Prior to Editas, Stacy spent 14 years at Genzyme and 6 years at Sanofi in corporate and business development roles of increasing responsibility within the oncology, transplant, multiple sclerosis (MS), and rare disease business units. She most recently served as Global Head of Rare Disease Business Development at Sanofi. Over the course of her career, she has had responsibility for leading all facets of business development and strategy including licensing, partnering and acquisition activities. Stacy received a Bachelor of Science degree in finance and economics at University of Massachusetts and a Master’s degree in Business Administration from the Darden School of Business at University of Virginia. In addition to her role at Editas, Stacy currently serves as a member of the Board of Trustees of Huntington’s Disease Society of America.
See All Sessions

Robert K. Coughlin
President & CEO of MassBio
As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to advance Massachusetts' leadership in the life sciences to grow the industry, add value to the healthcare system and improve patient lives. Over the last decade, Bob has truly become a champion for patients by ensuring innovative companies have the best environment possible to research, develop, and commercialize breakthrough therapies and cures for people around the world who need and deserve them.
See All Sessions

Peter J. Neumann
Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Cl
Peter J. Neumann, Sc.D., is Director of the Center for the Evaluation of Value and Risk in Health (CEVR) at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, and Professor of Medicine at Tufts University School of Medicine. He is the founder and director of the Cost-Effectiveness Registry, a comprehensive database of cost-effectiveness analyses in health care. Dr. Neumann has written widely on the role of clinical and economic evidence in pharmaceutical decision making and on regulatory and reimbursement issues in health care. He served as co-chair of the 2nd Panel on Cost-Effectiveness in Health and Medicine. He is the author or co-author of over 250 papers in the medical literature, the author of Using Cost-Effectiveness Analysis to Improve Health Care (Oxford University Press, 2005) and co-editor of Cost-Effectiveness in Health and Medicine, 2nd Edition (Oxford University Press, 2016). Dr. Neumann has served as President of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He is a member of the editorial advisory board of Health Affairs and the health policy advisory boards for the Congressional Budget Office. He has also held several policy positions in Washington, including Special Assistant to the Administrator at the Health Care Financing Administration. He received his doctorate in health policy and management from Harvard University.
See All Sessions

Clark Paramore
Head of Value Demonstration, bluebird bio
Clark Paramore, MSPH, is the Head of Value Demonstration at bluebird bio in Cambridge, MA. Mr. Paramore is responsible for creating and leading the value demonstration strategy for bluebird bio’s portfolio of gene therapies, including health economics and outcomes research evidence generation. Mr. Paramore is actively engaged in assessing the relevance and application of existing value frameworks for one-time transformative therapies, such as those being developed by bluebird bio. Prior to joining bluebird bio Mr. Paramore was Vice President and Senior Research Scientist at Evidera, Inc. in Lexington, MA. In this capacity, Mr. Paramore oversaw a range of scientific projects including economic models, systematic literature reviews, dossier development, and strategic consulting for biopharmaceutical clients in the area of value development/evidence generation for new products. His experience in pharmacoeconomics spans over 20 years with multiple publications in peer-reviewed journals.
See All Sessions

Terry Wilcox
Co-Founder & Executive Director, Patients Rising and Patients Rising Now
As co-founder and executive director of Patients Rising, Terry manages the organization’s day-to-day operations to help every patient gain access to the right treatment. An expert in multimedia storytelling, Terry uses her background in entertainment to present powerful personal patient narratives. She has a track record of building coalitions with survivors, caregivers and medical professionals. Her regular column in Women magazine profiles unsung patient advocates who are making a difference in their disease community. She has been interviewed by “The Stupid Cancer Show,” featured as a guest blogger for Critical Mass during “National Young Adult Cancer Week,” and served as the creative force and executive producer of Omni Health’s “Understanding Cancer” video series. Terry’s career in patient advocacy was inspired by her mentor Selma Schimmel, considered by many as the “original” young adult survivor advocate. As executive director for Vital Options International, Terry advanced Selma’s legacy at the nonprofit cancer communication, education and advocacy organization. From 2008 to 2014, Terry worked alongside Selma as creative director at Vital Options International and supervising producer for The Group Room.
See All Sessions